Baird analyst Robert Mason lowered the firm’s price target on Novanta (NOVT) to $160 from $169 and keeps a Neutral rating on the shares. The firm The firm updated its model following its mixed Q4 report. New products are driving the 2025 outlook which with upside possible if markets rebound.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NOVT: